Cutera, Inc., a medical device company, engages in the research, development, manufacture, marketing, and servicing of laser and energy-based aesthetics systems for practitioners worldwide. The company offers truSculpt flex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; truSculpt for the non-surgical body sculpting market; Juliet, a laser for women's intimate health; Secret RF, a fractional radio frequency microneedling device for skin revitalization; and enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions and acne scars. It also provides excel HR platform, a hair removal solution for various skin types; excel V+, a vascular and benign pigmented lesion treatment platform; and xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity. In addition, the company offers GenesisPlus, CoolGlide, myQ, and skincare products. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills, cycle refills, consumable tips, and marketing brochures through the company's website cutera.com. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, and other qualified practitioners, as well as for physicians performing aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1988 and is headquartered in Brisbane, California.
IPO Year: 2004
Exchange: NASDAQ
Website: cutera.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/22/2024 | Underperform → Mkt Perform | William Blair | |
| 7/27/2023 | $14.00 → $18.00 | Underweight → Neutral | Piper Sandler |
| 5/11/2023 | Outperform → Mkt Perform | William Blair | |
| 5/10/2023 | $14.00 | Underweight | Piper Sandler |
| 3/30/2023 | Buy → Hold | Maxim Group | |
| 1/31/2023 | Mkt Perform | William Blair | |
| 1/11/2023 | $85.00 → $33.00 | Overweight → Neutral | Cantor Fitzgerald |
| 12/28/2022 | $78.00 → $68.00 | Overweight | Stephens |
| 10/14/2022 | $78.00 | Overweight | Stephens |
| 11/4/2021 | $60.00 | Hold → Buy | Maxim Group |
4 - CUTERA INC (0001162461) (Issuer)
4 - CUTERA INC (0001162461) (Issuer)
4 - CUTERA INC (0001162461) (Issuer)
4 - CUTERA INC (0001162461) (Issuer)
4 - CUTERA INC (0001162461) (Issuer)
4 - CUTERA INC (0001162461) (Issuer)
4 - CUTERA INC (0001162461) (Issuer)
4 - CUTERA INC (0001162461) (Issuer)
4 - CUTERA INC (0001162461) (Issuer)
4 - CUTERA INC (0001162461) (Issuer)
10-Q - CUTERA INC (0001162461) (Filer)
8-K - CUTERA INC (0001162461) (Filer)
8-K - CUTERA INC (0001162461) (Filer)
10-Q - CUTERA INC (0001162461) (Filer)
8-K - CUTERA INC (0001162461) (Filer)
8-K - CUTERA INC (0001162461) (Filer)
DEFA14A - CUTERA INC (0001162461) (Filer)
DEFA14A - CUTERA INC (0001162461) (Filer)
DEFA14A - CUTERA INC (0001162461) (Filer)
DEF 14A - CUTERA INC (0001162461) (Filer)
SC 13G/A - CUTERA INC (0001162461) (Subject)
SC 13G/A - CUTERA INC (0001162461) (Subject)
SC 13D/A - CUTERA INC (0001162461) (Subject)
SC 13D/A - CUTERA INC (0001162461) (Subject)
SC 13D/A - CUTERA INC (0001162461) (Subject)
SC 13G/A - CUTERA INC (0001162461) (Subject)
SC 13G/A - CUTERA INC (0001162461) (Subject)
SC 13G/A - CUTERA INC (0001162461) (Subject)
SC 13G/A - CUTERA INC (0001162461) (Subject)
SC 13G - CUTERA INC (0001162461) (Subject)
William Blair upgraded Cutera from Underperform to Mkt Perform
Piper Sandler upgraded Cutera from Underweight to Neutral and set a new price target of $18.00 from $14.00 previously
William Blair downgraded Cutera from Outperform to Mkt Perform
Piper Sandler resumed coverage of Cutera with a rating of Underweight and set a new price target of $14.00
Maxim Group downgraded Cutera from Buy to Hold
William Blair initiated coverage of Cutera with a rating of Mkt Perform
Cantor Fitzgerald downgraded Cutera from Overweight to Neutral and set a new price target of $33.00 from $85.00 previously
Stephens reiterated coverage of Cutera with a rating of Overweight and set a new price target of $68.00 from $78.00 previously
Stephens resumed coverage of Cutera with a rating of Overweight and set a new price target of $78.00
Maxim Group upgraded Cutera from Hold to Buy and set a new price target of $60.00
Cutera collaborates with Dr. Edward Alvarez to provide truFlex® muscle stimulation treatments to help enhance the strength and endurance of adaptive athletes CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announces their partnership with the Adaptive Training Foundation (ATF), a non-profit organization that provides access and inclusion to individuals living with physical or traumatic impairments empowering them through exercise and community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112062983/en/Cutera, Dr. Edward Alvarez, and the Adaptive Training team at the ATF facility in D
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2024. Consolidated revenue for the third quarter of 2024 of $32.5 million Cash, cash equivalents, and restricted cash of $59.0 million AviClear growth of 16% vs prior year period driven by international capital system sales Global core capital growth of 7% on a sequential quarterly basis Full-year guidance maintained for both revenue and year-end cash balance "Our third quarter reflects consistent execution against our strategic priorities, with core capital sales improving on a sequential basis, AviClear continuing to
Cutera, Inc. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call at the following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remai
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024. Consolidated revenue for the second quarter of 2024 of $34.4 million Cash, cash equivalents, and restricted cash of $84.3 million AviClear growth of 41% vs prior year period driven by international capital system sales Service growth of 7% vs prior year period, highlighting improvements in field service and overall customer support Completion of the Q4 2023 corporate restructuring program, and announcement of additional cost reduction initiatives, allowing for both improved cost structure and better organization al
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, and its Japanese subsidiary, Cutera KK, are pleased to announce a strategic partnership with L'Oréal Japan Co. to exclusively promote, market, sell and distribute select SkinCeuticals products to medical and physician-led clinics in Japan. "We are excited about this collaboration with L'Oréal Japan Co. to bring SkinCeuticals' renowned skincare innovations to aesthetic providers in Japan," said Brent Hauser, Cutera's International President. "This agreement underscores our commitment to supporting our existing customer base by expanding access to high-quality skincare solutions that meet the unique needs
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the second quarter ended June 30, 2024, after the market closes on Thursday, August 8, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call by following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remain open u
New insights reveal the profound impact of acne and the growing interest in modern treatments Cutera, Inc. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announces the release of important new acne survey data as part of June's Acne Awareness Month. The findings highlight the impact of acne on individuals and emphasize the substantial role of novel treatments like AviClear®, the first FDA-cleared energy-based device for the long-term treatment of mild, moderate, and severe inflammatory acne, in improving quality of life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613634097/en/(Graphic: Busines
Experienced Healthcare Executive Brings Extensive Financial and Operational Expertise to Cutera Board of Directors CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that Jeryl "Jeri" Hilleman will join its Board of Directors, effective July 12, 2024. Ms. Hilleman brings over 30 years of experience in the healthcare industry, with a proven track record in financial leadership, strategic planning, operational excellence, and corporate governance. Her extensive background in life sciences and medical technology, both as a public company CFO and as a corporate director, will be invaluable to Cutera as it continues to innovate, drive towar
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will hold an investor webinar at 11 a.m. PDT on June 20, 2024, to present an overview of AviClear, the first FDA-cleared energy device for the long-term treatment of mild, moderate, and severe inflammatory acne. The webinar will include a review of clinical data, market opportunity, future clinical studies, and real-world user experience. The AviClear Investor Webinar will feature presentations by Cutera CEO Taylor Harris, EVP and CTO Michael Karavitis, SVP of Global Marketing Steve Kreider, as well as leading dermatologists David J. Goldberg, MD, JD, and Sonia Batra, MD, MSc, MP
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, granted a total of 44,500 non-qualified inducement stock options to six employees. These awards were approved by the Compensation Committee of Cutera's Board of Directors. The stock options have an exercise price of $2.23, equal to the closing price of Cutera common stock on the grant date of May 13, 2024. A quantity of 25% shall vest annually, and 1/48 of the grant total shall vest each month thereafter, subject to continued employment, for a total of 29,500 stock options granted to five employees. A quantity of 33% shall vest annually, and 1/36 of the grant total shall vest
Experienced Healthcare Executive Brings Extensive Financial and Operational Expertise to Cutera Board of Directors CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that Jeryl "Jeri" Hilleman will join its Board of Directors, effective July 12, 2024. Ms. Hilleman brings over 30 years of experience in the healthcare industry, with a proven track record in financial leadership, strategic planning, operational excellence, and corporate governance. Her extensive background in life sciences and medical technology, both as a public company CFO and as a corporate director, will be invaluable to Cutera as it continues to innovate, drive towar
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step
Hauser Brings Over 20 Years of Aesthetics Industry Experience in Markets Across the Globe Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Brent Hauser as President, International, effective October 2, 2023. Mr. Hauser will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for commercial performance in existing international markets, expansion into new geographies, and the international launch of AviClear, the company's pioneering energy-based device for the treatment of mild to severe acne, in 2024. Mr. Hauser brings over 20 years of aest
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Jeff Jones as Chief Operating Officer, effective August 28, 2023. This move underscores Cutera's commitment to delivering world-class product quality, reliability, and service to customers. Mr. Jones will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for end-to-end operations, including manufacturing, quality, supply chain, field service engineering, and customer service. Jeff brings a wealth of experience, having spent 35 years in operational roles within the medical device industry, incl
Follows Comprehensive Search Process; Brings Over 20 Years of Healthcare Industry Experience and Operational Expertise CUTERA, INC. ("Cutera" or the "Company") (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today announced that Taylor Harris has been appointed Chief Executive Officer, effective August 7, 2023. Mr. Harris will succeed Sheila Hopkins, who has been serving as Interim Chief Executive Officer since April 2023. Mr. Harris and Ms. Hopkins will both continue serving as members of Cutera's Board of Directors. Mr. Harris joined Cutera's Board in June 2023. He is a proven executive and brings over 20 years of operational expertise as well as healthcare a
Accomplished finance leader joins SetPoint Medical as it advances its development of a novel neuroimmune modulation platform for rheumatoid arthritis SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the appointment of Rohan Seth as Chief Financial Officer (CFO). "I am excited to welcome Rohan to the SetPoint leadership team," said Murthy Simhambhatla, Ph.D., President and CEO of SetPoint Medical. "Rohan's proven track record of success in managing finance and business development functions will be instrumental as we continue to advance our therapeutic platform through clinical development." "I am honored to j
Resolves Dispute with Former CEO David Mowry CUTERA, INC. ("Cutera" or the "Company") (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today commented on the termination of the proxy solicitation by Voce Capital Management LLC ("Voce Capital") with respect to the Special Meeting of Stockholders, scheduled for June 9, 2023 (the "Special Meeting"). Cutera issued the following statement: The Special Committee of the Cutera Board of Directors deeply values the constructive engagement we have had with our stockholders over recent weeks. The Board refreshment we announced on May 9, 2023, followed an agreement with two of our largest stockholders, which collectively
Clarify What This Campaign is About and What it is Not Cite Recent Value-Destructive Actions of the Special Committee as Further Support for Reconstituting the Board Highlight Multiple False and Misleading Statements from the Special Committee Today J. Daniel Plants, Founder and Chief Investment Officer of Voce Capital Management LLC and a member of the Board of Directors (the "Board") of Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), and David Mowry, also a Cutera Director – who together own approximately 7.0% of the outstanding shares of Cutera – issued the following statement in response to a recent press release from the Special Committee of Cutera's Board: "The events
Independent Board Member Sheila A. Hopkins Appointed Interim CEO; Search for Permanent CEO Underway Janet D. Widmann Appointed Independent Chair Executive Chairman Daniel Plants and CEO David Mowry Terminated for Cause Withdraws 2023 Outlook CUTERA, INC. (the "Company") (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today announced significant changes to the Company's executive leadership to focus on improving performance and results. The Board of Directors (the "Board") has appointed Sheila A. Hopkins as Interim Chief Executive Officer ("CEO") and Janet D. Widmann as Independent Chair of the Board, effective immediately. The Board's search for a permanent
Mr. Plants will join Strategic Review and Human Resources Committees Argo Group International Holdings, Ltd. (NYSE:ARGO) ("Argo" or "the Company") today announced the August 4, 2022 appointment of J. Daniel Plants as an independent member of the Company's board of directors (the "Board"). Mr. Plants is a seasoned investor, financial executive and senior advisor with three decades of experience helping companies successfully navigate change and unlock shareholder value. He currently serves as Chief Investment Officer of Voce Capital Management LLC, which he founded in 2011 after working at several leading financial institutions, including in executive positions in the mergers and acquisiti
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2024. Consolidated revenue for the third quarter of 2024 of $32.5 million Cash, cash equivalents, and restricted cash of $59.0 million AviClear growth of 16% vs prior year period driven by international capital system sales Global core capital growth of 7% on a sequential quarterly basis Full-year guidance maintained for both revenue and year-end cash balance "Our third quarter reflects consistent execution against our strategic priorities, with core capital sales improving on a sequential basis, AviClear continuing to
Cutera, Inc. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call at the following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remai
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024. Consolidated revenue for the second quarter of 2024 of $34.4 million Cash, cash equivalents, and restricted cash of $84.3 million AviClear growth of 41% vs prior year period driven by international capital system sales Service growth of 7% vs prior year period, highlighting improvements in field service and overall customer support Completion of the Q4 2023 corporate restructuring program, and announcement of additional cost reduction initiatives, allowing for both improved cost structure and better organization al
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the second quarter ended June 30, 2024, after the market closes on Thursday, August 8, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call by following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remain open u
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today reported financial results for the first quarter ended March 31, 2024. Consolidated revenue for the first quarter of 2024 of $38.8 million. Strong sequential increase in AviClear revenue, driven by a business model shift in North America and a successful initiation of the International limited commercial release, during the first quarter of 2024. Recent highlights include the launch of xeo+ and the inaugural session of Cutera Academy, focused on equipping customers with the tools to build successful AviClear practices. "I am pleased with our progress in the fi
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 9, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m. ET) that same day. Participants can register for the conference call at the following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Re
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today reported financial results for the fourth quarter and full-year ended December 31, 2023. Consolidated revenue for the fourth quarter of 2023 of $49.5 million Full-year 2023 revenue of $212.4 million, ahead of guidance of approximately $205 million Cash and marketable securities of $143.6 million as of December 31, 2023, ahead of guidance of approximately $135 million Completion of corporate restructuring program, allowing for both an improved cost structure and better organizational alignment Successful execution of the North American limited commercial rel
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Thursday, March 21, 2024. The Company intends to file its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 and restated Quarterly Reports for the first and second quarters of 2023 in the week beginning March 4, 2024. As previously reported, the delay in filing the Quarterly Reports was due to the identification of an inventory shortfall relative to the system of record. Due to the time-consuming nature of th
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today provided preliminary financial results for the third quarter ended September 30, 2023, as well as recent business updates. Some Company highlights: Consolidated revenue for the third quarter of 2023 of $46.5 million, a decrease of 26% compared to the third quarter of 2022 Cash and marketable securities of $179.5 million as of the end of the third quarter Announcement of an enhanced AviClear offering, including the option to purchase the device upfront with a corresponding reduction in treatment costs Initiation of a global restructuring program, expected to sa
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the third quarter of 2023 after the market close on Wednesday, November 8, 2023. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m. ET) that same day. To join the conference call, dial 1-800-319-4610 (domestic) or +1-631-891-4304 (international) and ask to join Cutera's earnings conference call. The call will also be webcast and can be accessed from the Investor Relations section of Cutera's website at http://www.cutera.com/. The webcast repl
Stephens & Co. analyst George Sellers reiterates Cutera (NASDAQ:CUTR) with a Overweight and maintains $10 price target.
Piper Sandler analyst Matt O'Brien maintains Cutera (NASDAQ:CUTR) with a Neutral and maintains $3 price target.
- SEC Filing
Cutera (NASDAQ:CUTR) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(1.00) by 9 percent. This is a 13.49 percent increase over losses of $(1.26) per share from the same period last year. The company reported quarterly sales of $38.793 million which beat the analyst consensus estimate of $37.325 million by 3.93 percent. This is a 28.85 percent decrease over sales of $54.526 million the same period last year.
Gainers OneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million. Aesthetic Medical Intl (NASDAQ:AIH) shares rose 43.48% to $0.49. The market value of their outstanding shares is at $23.1 million. Sight Sciences (NASDAQ:SGHT) shares rose 20.77% to $6.57. The market value of their outstanding shares is at $325.5 million. Inspire Veterinary (NASDAQ:IVP) stock increased by 16.59% to $0.05. The market value of their outstanding shares is at $1.7 million. GlycoMimetics (NASDAQ:GLYC) stock rose 6.41% to $3.15. The market value of their outstanding shares is at $203.0 million. As per t
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 0.3% on Friday. The Dow traded down 0.49% to 39,585.67 while the NASDAQ rose 0.26% to 16,444.91. The S&P 500 also rose, gaining, 0.01% to 5,241.56. Check This Out: These 3 Risk Off Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts Leading and Lagging Sectors Communication services shares jumped by 0.8% on Friday. In trading on Friday, real estate shares fell by 1.1%. Top Headline Shares of Lululemon Athletica Inc. (NASDAQ:LULU) fell more than 15% during Friday’s session after releasing fourth-quarter results. Lululemon posted better-than-
Shares of Cutera, Inc. (NASDAQ:CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results. Cutera posted adjusted loss of $1.36 per share, compared to market estimates for a loss of 94 cents per share. The company’s quarterly sales came in at $49.540 million, versus expectations of $47.500 million, according to data from Benzinga Pro. Cutera shares dipped 26.5% to $1.6899 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Murano Global Investments PLC (NASDAQ:MRNO) shares jumped 147.5% to $23.94 after falling 46% on Thursday. Nova LifeStyle, Inc. (NASDAQ:NVFY) surged 120% to $4.0301 afte
Gainers IMAC Hldgs (NASDAQ:BACK) shares moved upwards by 91.5% to $2.47 during Friday's regular session. The market value of their outstanding shares is at $2.8 million. Virios Therapeutics (NASDAQ:VIRI) shares increased by 37.98% to $0.46. The company's market cap stands at $8.8 million. Regencell Bioscience (NASDAQ:RGC) stock increased by 36.71% to $5.25. The company's market cap stands at $68.3 million. Ontrak (NASDAQ:OTRK) shares moved upwards by 35.03% to $0.35. The market value of their outstanding shares is at $9.6 million. Outlook Therapeutics (NASDAQ:OTLK) shares rose 27.13% to $8.95. The market value of their outstanding shares is at $193.1 million. Biolase (NASDAQ:BIOL) shar
Stephens & Co. analyst George Sellers reiterates Cutera (NASDAQ:CUTR) with a Overweight and maintains $10 price target.